Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Day One Biopharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 4 York Charles N II (COO, CFO and Secretary) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 922 shares @ $13.86, valued at $12.8k
Exercised 1,375 restricted stock units @ $0
Exercised 2,250 restricted stock units @ $0
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 8-K Investor presentation
Docs: "Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience",
"Corporate Presentation"
08/10/2023 SC 13G/A FMR LLC reports a 6.9% stake in DAY ONE BIOPHARMACEUTICALS INC
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Investor presentation, Quarterly results
Docs: "Day One Reports Second Quarter 2023 Financial Results and Corporate Progress Results from FIREFLY-1 demonstrate overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma evaluable patients presented at the 2023 American Society of Clinical Oncology Annual Meeting Initiated rolling submission of the tovorafenib New Drug Application in relapsed or progressive pediatric low-grade glioma in May 2023 The Company expects to complete the rolling submission of the tovorafenib NDA by October 2023 Completed $172.5 million public offering, strengthening balance sheet and extending cash runway into 2026",
"2 PO QW DAY101 QW"
07/05/2023 4 Bender Jeremy (CEO) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Disposed of 240,288 shares @ $0
Acquired 240,288 shares @ $0
Gifted 240,288 shares @ $0
Gifted 240,288 shares @ $0
Gifted 240,288 shares @ $0
Gifted 240,288 shares @ $0
Gifted 59,737 shares @ $0
Gifted 59,737 shares @ $0
Gifted 29,938 shares @ $0
Gifted 29,938 shares @ $0
06/12/2023 SC 13D/A AI Day1 LLC reports a 13.2% stake in Day One Biopharmaceuticals, Inc.
06/12/2023 4 AI Day1 LLC (10% Owner) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Bought 769,230 shares @ $13, valued at $10M
06/12/2023 8-K Investor presentation
Docs: "Corporate Presentation"
06/07/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"Day One Announces Pricing of Public Offering of Common Stock BRISBANE, Calif., June 6, 2023 - Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All shares of common stock are being offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $150.0 million. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,730,769 shares of..."
06/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/07/2023 4 Blackman Samuel C. (Chief Medical Officer) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 1,229 shares @ $16, valued at $19.7k
06/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/06/2023 8-K Other Events  Interactive Data
06/05/2023 144 Form 144 - Report of proposed sale of securities:
05/17/2023 4 York Charles N II (COO, CFO and Secretary) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 955 shares @ $13.1223, valued at $12.5k
Exercised 1,375 restricted stock units @ $0
Exercised 2,250 restricted stock units @ $0
05/17/2023 4 Blackman Samuel C. (Chief Medical Officer) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 692 shares @ $13.1223, valued at $9.1k
Exercised 1,187 restricted stock units @ $0
Exercised 1,437 restricted stock units @ $0
05/17/2023 4 Bender Jeremy (CEO) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 3,104 shares @ $13.1223, valued at $40.7k
Exercised 3,562 restricted stock units @ $0
Exercised 4,750 restricted stock units @ $0
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/01/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 8-K Investor presentation, Quarterly results
Docs: "Day One Reports First Quarter 2023 Financial Results and Corporate Progress FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre-New Drug Application meeting held April 19, 2023 with U.S. Food and Drug Administration for tovorafenib for relapsed or progressive pediatric low-grade glioma Company to host conference call on June 4th at 6:00 PM CT",
"2 PO QW DAY101 QW"
04/20/2023 8-K Quarterly results
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/20/2023 8-K Quarterly results
03/14/2023 4 Blackman Samuel C. (Chief Medical Officer) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 10,000 shares @ $18.0484, valued at $180.5k
03/08/2023 4 Bender Jeremy (CEO) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 12,500 shares @ $20.0091, valued at $250.1k
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Investor presentation, Quarterly results
Docs: "Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for presentation at a medical meeting in second quarter of 2023 New Drug Application submission planned for tovorafenib in first half of 2023",
"2 PO QW DAY101 QW"
02/23/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Day One Biopharmaceuticals, Inc. (as amended and restated on February 17, 2023)",
"Amended and Restated Bylaws of Day One Biopharmaceuticals, Inc. (as amended and restated on February 17, 2023)"
02/21/2023 4 York Charles N II (COO, CFO and Secretary) has filed a Form 4 on Day One Biopharmaceuticals, Inc.
Txns: Sold 9,377 shares @ $20.0267, valued at $187.8k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy